CERo Capital Lease Obligations vs Total Current Liabilities Analysis
| CERO Stock | 0.06 0.01 18.68% |
CERo Therapeutics financial indicator trend analysis is way more than just evaluating CERo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CERo Therapeutics is a good investment. Please check the relationship between CERo Therapeutics Capital Lease Obligations and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Capital Lease Obligations vs Total Current Liabilities
Capital Lease Obligations vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CERo Therapeutics Capital Lease Obligations account and Total Current Liabilities. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between CERo Therapeutics' Capital Lease Obligations and Total Current Liabilities is -0.54. Overlapping area represents the amount of variation of Capital Lease Obligations that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of CERo Therapeutics Holdings,, assuming nothing else is changed. The correlation between historical values of CERo Therapeutics' Capital Lease Obligations and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Lease Obligations of CERo Therapeutics Holdings, are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Capital Lease Obligations i.e., CERo Therapeutics' Capital Lease Obligations and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.54 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Capital Lease Obligations
CERo Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to CERo Therapeutics asset purchases. For example, CERo Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as CERo Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.Total Current Liabilities
Total Current Liabilities is an item on CERo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CERo Therapeutics Holdings, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from CERo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CERo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. As of the 13th of December 2024, Selling General Administrative is likely to drop to 2,748. In addition to that, Enterprise Value Over EBITDA is likely to drop to -31.51
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 986.7K | 142.1K | 127.9K | 121.5K | Net Interest Income | 986.7K | 142.1K | 127.9K | 121.5K |
CERo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CERo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with CERo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against CERo Stock
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.66 | LLY | Eli Lilly | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.58 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings, to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.